Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples

In this podcast episode, listen to Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss management of patients with multiple myeloma from a recent symposium during the annual hematology meeting in 2021.
Brian G.M. Durie, MD
Thomas G. Martin, MD
Philippe Moreau, MD
S. Vincent Rajkumar, MD
Jesús F. San-Miguel, MD, PhD
Released: February 18, 2022

In this episode, Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases.

  • Smoldering myeloma
  • Induction therapy for autologous stem cell transplant–eligible patients
  • First-line approaches for autologous stem cell transplant–ineligible patients
  • Treatment after first relapse
  • Selecting therapy for heavily pretreated myeloma

Information on this Educational Activity

Faculty

Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda and fees for non-CME/CE services from Amgen.
Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director,
Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received funds for research support from Amgen, Johnson & Johnson/Janssen, Sanofi, and Seattle Genetics and consulting funds from GlaxoSmithKline and Oncopeptides.
Philippe Moreau, MD

Professor of Clinical Hematology
Head,
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, Oncopeptides, and Sanofi.
S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

S. Vincent Rajkumar, MD, has no relevant conflicts of interest to report.
Jesús F. San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio, and Takeda.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Oncopeptides
Pfizer, Inc.
Sanofi Genzyme

Related Content

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings